105772-13-2

Basic information

• Product Name: 3,6-Dihydro-2H-pyran-4-carbonitrile
• Synonyms: 3,6-Dihydro-2H-pyran-4-carbonitrile;2H-Pyran-4-carbonitrile, 3,6-dihydro-
• CAS NO: 105772-13-2
• Molecular Formula: C₆H₇NO
• Molecular Weight: 109.12588
• Mol File: 105772-13-2.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3,6-Dihydro-2H-pyran-4-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3,6-Dihydro-2H-pyran-4-carbonitrile(105772-13-2)
• EPA Substance Registry System: 3,6-Dihydro-2H-pyran-4-carbonitrile(105772-13-2)

Safety Data

• Hazardous Substances Data: 105772-13-2(Hazardous Substances Data)

Usage

General Description

3,6-Dihydro-2H-pyran-4-carbonitrile is a chemical compound with the molecular formula C7H7NO. It is a heterocyclic compound that contains a pyran ring and a carbonitrile group. 3,6-Dihydro-2H-pyran-4-carbonitrile is commonly used as a building block in organic synthesis and medicinal chemistry. It has potential applications in the pharmaceutical industry for the development of new drugs and biologically active compounds. 3,6-Dihydro-2H-pyran-4-carbonitrile has also been found to exhibit antimicrobial and antifungal properties, making it a promising candidate for the treatment of various infections. Overall, this chemical compound has diverse potential uses and is of interest to researchers in various fields.

Upstream product

• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 773837-37-9 sodium cyanide 
• 50289-10-6 4-hydroxy-tetrahydropyran-4-carbonitrile 
• 7677-24-9 trimethylsilyl cyanide 

Relevant articles and documents

The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic Properties

The discovery of a potent selective low dose Janus kinase 1 (JAK1) inhibitor suitable for clinical evaluation is described. As part of an overall goal to minimize dose, we pursued a medicinal chemistry strategy focused on optimization of key parameters th

FACTOR XIIA INHIBITORS

This invention relates to compoundsof formula (I)and methods of treatment using the compounds. The invention also relates to processes and methods for producing the compounds of the invention. The compounds of the invention are modulators of Factor XII (e.g. Factor XIIa). In particular, the compounds are inhibitors of Factor XIIa and may be useful as anticoagulants.

AMINOPYRAZOLES AS JANUS KINASE INHIBITORS

The instant invention provides compounds which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.